Donate

• KRF is the leading ketamine assisted psychotherapy organization in the world.
• We have developed as the free-standing research organization developing the options for utilizing ketamine to benefit human beings.
• We are the preeminent training organization with over 1100 practitioners trained. We are producing Eight or more major programs in 2025-2026. 
• Our Ketamine Training Center is originating new programs to access KAP with our annual Advanced Sharing and our Dharma-K exploration of the integration of spirit and spiritual practices with the meditative expansiveness of the ketamine experience. Dharam K will be having its fourth annual program in May of 2026.
• Our Ketamine Psychotherapy Associates (KPA) membership organization has grown to over 100 practitioners with new members joining frequently
• We remain the only organization with Access to Care available to KPA members offering financial support to those who cannot afford treatment.
• We are publishing our work and generating public awareness. Recognition of KRF is growing rapidly.
• We have been publishing mass circulation articles on the proper use of ketamine as an assisted psychotherapy and on the issues of misuse and abuse—prevention, motivation, seeking help, and treatment. We have initiated Instagram and TikTok series to reach younger people and diverse populations.
• We have opened the door to treating adolescents and their families with our recent publication in Frontiers of Psychiatry.
• We published a definitive article in Frontiers of Psychiatry on Ketamine and KAP in 2024.
• We are in a relationship with Progressive ‘Therapeutics Inc (PTI), which shares development perspectives, patent, and mutual assistance. 

Overview: As a free standing research institute, we are able to design and perform unique and beneficial research given the legal status of ketamine—WHO/worldwide.  Developing protocols to be funded and administered under KRF’s non-profit umbrella, KRF has advantages that are creative to alleviate human suffering and engender healing. We welcome new initiatives to take place under our umbrella and forming relationships with collaborating researchers. 

Each project has its own cost center and donors to KRF may earmark their contributions. 

When conducting primary clinical research  KRF submits our protocols for approval to the FDA for an IND  and to  wcgIRB. Once approved  we delineate our projects on clinicalstudies.gov

Our Program Initiatives

The Phantom Limb Pain Protocol—FDA and IRB approved. We will begin subject accrual in January for what we believe to be of great benefit to those suffering with the physical and emotional aftermaths of trauma and amputations. Our goal is to establish the protocol for application worldwide.

Ketamine has indications for potential benefit for a variety of pain disorders, including phantom limb pain. Based on a profound anecdote (our story appearing in Lucid News), we are conducting a proof of concept study to assess ketamine’s potential benefit for this syndrome that causes so much suffering. 

We are pleased to report  that In October of 2025, we received FDA and IRB approval for our study and will begin patient recruitment in January 2026. The study will be conducted at 4 sites with a goal of 30 -patients assessed and treated over a six month period with a 12 month follow-up.

$218,000 is our budget

International Protocol for Ketamine Treatment of Acute Emotional Trauma and Distress

In awareness of ketamine’s potential for the treatment of acute agitation, suicidality, and PTSD, and in response to the many horrors being visited on humans, we have developed  ketamine protocols for the treatment of emotional reactions to acute traumatization. We have sent out our protocol as widely as possible in an effort to provide a guide to ketamine’s use as therapeutics applicable to acute trauma. KRF is serving as an initiator and a ground to which practitioners may turn. 

This is a collaboration and to that end we are building an international body, what we are calling the ICG, to create the conditions for applying ketamine and other modalities for acute care. This is unprecedented and have a literature and growing experience to validate our methodology. Intensive feedback from those on the ground is essential. This is a cooperative project and will grow in its scope and needs. It is created in the spirit of service and beyond borders with the intention of caring, kindness and sharing.

We are directly supporting trauma work with ketamine in the Ukraine. Our attempt to provide trauma training with ketamine in Israel/Palestine continues—with difficulties and some success in having practitioners administer the protocol. In disaster recovery, the protocol was used following the devastating flood in North Carolina.

$35,000 is our budget   

Ketamine for Menstrually Related Disorders—PMS and PMDD

KRF has focused on Women’s Health and wellbeing with a new project to demonstrate the effectiveness of ketamine for PMS and PMDD. We are pleased to report that we are successfully navigating the FDA IND approval process and have breakthroughs in the first use of sublingual lozenges with esketamine and at home use of esketamine. Our low dose format treats the symptoms of PMDD as they arise. 

Previously, based on our clinical experience through our sister Center for Transformational Psychotherapy, we conducted a small study demonstrating the extraordinary effectiveness of low dose ketamine given in response to the arising of symptoms of PMS/PMDD. This led to a use patent for this indication, the benefit of patenting being widespread access. 

It is our strong belief that women worldwide will benefit from episodic use on an intermittent basis with provision for at-home administration as needed. This is a breakthrough for women suffering in the luteal phase of the menstrual cycle providing a restitution of well-being and presence.

Our protocol is nearing completion with the FDA with their approval of its essential features. We have had to perform elaborate lab testing as per the FDA’s demand which was completed at the end of October. After IRB approval,  we will open the study to subjects in the first quarter 2026.  We anticipate that once begun, the project will take a year or a bit more to complete its clinical process.

$225,000 is our budget 

The KRF ‘Guidelines for Personal Use and the Clinical Administration of Ketamine—Safety and Standard of Care’ is in preparation for a second Edition that adds to the depth of understanding and treating the potentiality for dependency and dependency. Our Guidelines have reached over 2.5 million recipients (that we are aware of), have a Spanish language version30,00 and are available as Kindle books. We are contemplating issuing a print version as Edition 2 is a significant enlargement of content.

The Guidelines are distributed  without cost. The Kindle versions are available for $1.

KRF has taken this leadership position in recognition of our awareness of the growing problem of ketamine dependency worldwide. Our work seeks to reach both those who are using ketamine personally and those who are contemplating entering a clinical program in which ketamine will be administered to them.

$30,000 is our budget

The Post-Partum Depression Protocol

The Foundation has patented the use of ketamine for Post-Partum Depression (PPD) which is novel.  We are in protocol development for a multi-site PPD KAP model treatment program which we believe will demonstrate great success in benefitting new mothers without affecting breast feeding or exposing infants to medications. Our groundbreaking ketamine and lactation study has assured us of this.  Anticipated project initiation is in Summer 2026. 

This will be a complex clinical study as the condition is varied and personal with environmental aspects that need to be encompassed in a model treatment program in which ketamine administration is a major but not the only component. Of importance is the use of ketamine as the first significant therapeutic medication to be initiated in treatment. It will be a further demonstration of ketamine’s appropriate use as the primary antidepressant. 

There Is great interest in this as a significant new treatment for women suffering with PPD.

$500,000 is our budget which will be in review until the protocol is formalized and submitted to FDA

The KAP Clinical Review 

As the creator and initiator of KAP, we published our study of 235 patients in  2019. It remains the cornerstone of KAP’s success story. In the intervening years, we have accumulated experience and data for over 1000 additional patients, digitized in Vanderbilt University’s Redcap program, making it highly accessible for us to publish a major new report to the field. This project entails completing the patient charts under HIPAA compliance and with our statistician compiling the data and its presentation for a paper that in high detail reflects KAP practice.  

We are beginning with the smaller number of our Adolescent Patients as there is no clinical report in the literature, other than our qualitative paper for the application of KAP to adolescents—and their families. 

$75,000 is our budget